脂质体
体内
医学
药物输送
药理学
靶向给药
药品
化学
纳米技术
生物
材料科学
生物化学
生物技术
作者
Tatyana Levchenko,William C. Hartner,Vladimir P. Torchilin
出处
期刊:Therapeutic Delivery
[Newlands Press Ltd]
日期:2012-04-01
卷期号:3 (4): 501-514
被引量:34
摘要
Liposome-based pharmaceuticals used within the cardiovascular system are reviewed in this article. The delivery of diagnostic and therapeutic agents by plain liposomes and liposomes with surface-attached targeting antibodies or polyethylene glycol to prolong their circulation time and accumulation at vascular injuries, ischemic zones or sites of thrombi are also discussed. An overview of the advantages and disadvantages of liposome-mediated in vitro, ex vivo and in vivo targeting is presented, including discussion of the targeting of liposomes to pathological sites on the blood vessel wall and a description of liposomes that can be internalized by endothelial cells. Diagnostic liposomes used to target myocardial infarction and the relative importance of liposome size, targetability of immunoliposomes and prolonged circulation time on the efficiency of sealing hypoxia-induced plasma membrane damage to cardiocytes are discussed as a promising approach for therapy. The progress in the use of targeted liposomal plasmids for the transfection of hypoxic cardiomyocytes and myocardium is presented. Stent-mediated liposomal-based drug delivery is also reviewed briefly.
科研通智能强力驱动
Strongly Powered by AbleSci AI